Kerdan Group

Industry: Consulting

Annual Revenue Estimate: NA

AUM: NA

Email Convention: NA

Overview

Overall Ranking (NA)

The Overall Ranking is a score from 1 star (very bad) to 5 stars (excellent) generated based on the Company Reviews of current and former employees at this company, taking everything into account.

The number you see in the middle of the donut pie chart is the simple average of these scores. If you hover over the various sections of the donut, you will see the % breakdown of each score given.

The percentile score in the title is calculated across the entire Company Database and uses an adjusted score based on Bayesian Estimates (to account for companies that have few reviews). Simply put, as a company gets more reviews, the confidence of a "true score" increases so it is pulled closer to its simple average and away from the average of the entire dataset.

The Overall Ranking is generated based on the Company Reviews.

Not Enough Data
  • 5 Stars
  • 4 Stars
  • 3 Stars
  • 2 Stars
  • 1 Star

Company Details

We are a boutique strategy consulting firm based out of Kendall Square, the biotech center of Cambridge, MA. We work with biopharma development and disease area teams, bringing experience, perspective, objectivity, and fresh ideas to the major strategic decisions that they face:

* Asset Development Strategy
* Disease Area Strategy and Proof of Concept Definition
* Insight Book Creation
* Process and Capability Design

Since Kerdan was founded by Thom Doyle and Matt Hall in 2001, we've worked with 7 of the top 10 global biopharma companies. In metabolic, cardiovascular, ophthalmologic, oncologic, CNS, and inflammatory disease areas, we have helped our clients dream up great ideas about developing better medicines.

Underlying our work is a mindset and approach we call inspire-prototype-adapt. Given the complexities and uncertainties in drug development, we believe this mindset is necessary to overcome adversity and maximize serendipity. Our clients--leaders trying to deliver real benefits to patients-- don't believe that the system is unchangeable. Their success rests on their ability to look forward. They require a creative process to generate new, better alternatives.

Our approach creates better options because it rests on open-minded collaboration, skilled observation and inquiry, and prototyping to continually advance our clients' and our own thinking. The result is a proactive approach to create the future out of what is now whitespace.
Specialties
drug development strategy

Locations

Location

Cambridge

See in Google Maps

139 Main Street, Cambridge, MA, 02142, United States

617-252-6530

Get Full Access

or Register to Contribute